SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : ADVR - Bulls no Bears

 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  
To: DAN LITTLE who wrote (831)9/28/1997 11:41:00 PM
From: Kingfisher   of 913
 
Dan, I certainly hope that readers of all the SI ADVR threads have read Dr. Hirschman's
interview from the year old SEPTEMBER 1996 Infectious Disease News interview by now,
but if they havn't it was nice of you to supply the URL you identified in Post #834

Joe, the SEPTEMBER 1996 Infectious Disease News article is the one I referred to in
Post #810 on this Thread when trying to make laymen comparisons of the scientific efforts
being pursued at Cel-Sci, United Biomedical and Hybridon to those being pursued by
Dr. Hirschman. I ended that post with the following statement in order to emphasize
that we are no longer talking about Reticulose's effectiveness against VIRUSES but, it's
effectiveness against CANCER.

It is rumored that Government Scientists are ecstatic over the results of very recent
important investigations into how Reticulose stimulates the immune system to make
TUMOR NECROSIS FACTOR and GAMMA INTERFERON. The TUMOR NECROSIS FACTOR kills and shrinks the
CANCER and the GAMMA INTERFERON strengths the cell wall to resist infection. So what this
all means is that Reticulose has a two prong approach in
dealing with CANCER,
one offensive, where the IMMUNE SYSTEM ATTACKS AND KILLS THE
CANCER and the other
defensive where the BODY IS STIMULATED TO RESIST INFECTION.
And to top all of this, Reticulose
is non toxic [no side effects], which is something that has been known and stated over and over
again for the past 60-YEARS.

Since its own scientists are now verifying Dr. Hirschman' findings, how the heck is it
possible for the FDA not to approve Reticulose and/or even continue to take more unwarranted
time based on a very bad policy decision they made in 1962?
Don't you think it is
disturbing and preposterous that the continued existence of
Reticulose is up to the FDA?
The FDA has not only keep Reticulose of the shelves since 1962 but now for also MORE THAN ONE YEAR
after Dr. Hirschman provided an abstract, a full JIM article and had the Infectious Disease News
interview. These papers provide ample evidence of its effectiveness against CANCER. How can the
FDA continue their restraining action even after their own scientists
understand what Reticulose is
and its benefit to mankind?

Unfortunately, I feel that the FDA is controlled to an extent that none of us can perceive.
If the persons presently in charge of the FDA cannot understand what
RETICULOSE now means to
the treatment of CANCER, let alone VIRUSES, and do not immediate approve it for use,
the american people are being scamed by unscrupulous or incompetent government scientific administrators.
THE EVIDENCE IS IN < even though ADVR continues to not have provided more public news releases
to support the evidence.

I do not like to think that the FDA may be composed of unscrupulous or incompetent government
scientific administrators. Therefore I feel that the FDA can do nothing but approve the
dispensing of Reticulose. They know and understand the urgency and
have to act accordingly.
Thus, based on Dr, Hirschman's recent scientific evidence, it is self evident that the FDA has to
approve Reticulose almost immediately. They simply have no choice.

Regrettably I felt this way last year but I did not express myself on the Thread.
God help us if I feel this way next year and Reticulose has still not been approved.

The Kingfisher.
Report TOU ViolationShare This Post
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext